Dalcetrapib vs Obicetrapib/ezetimibe (Evlarco)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline
Dalcetrapib
Developed by DalCor Pharmaceuticals under a licence from Roche
NCT01516541 · Phase 3 · completed
The study was randomized and double-blind, compared dalcetrapib with placebo, and enrolled 2,220 participants. Its primary endpoint was a hard clinical composite cardiovascular outcome, but the comparison cannot be judged because trial results have not been posted.
Next expected readout: August 2027 · NCT05918861 (registry estimate)
Reported efficacy
Incidence of Cardiovascular Mortality and Morbidity (From date of randomization to first event up to 48 months): Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). (missed)
Result source: NCT00658515
Obicetrapib/ezetimibe (Evlarco)
Marketed by A. Menarini under a licence from NewAmsterdam Pharma
NCT06005597 · Phase 3 · completed
The study was randomized, quadruple-blind, and placebo- and active-controlled, with 407 participants distributed across four treatment groups. All four prespecified LDL-C comparisons significantly favored the obicetrapib-containing treatment, but LDL-C is a laboratory surrogate rather than a hard clinical endpoint, so the evidence is rated moderate.
Reported efficacy
Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C (84 Days); Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C (84 Days): Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) (met)
Result source: NCT06005597
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dalcetrapib | Obicetrapib/ezetimibe (Evlarco) |
|---|---|---|
| LDL-C, % change | —Not posted · NCT01516541 | —Not reported |
| Non-HDL-C, % change | —Not posted · NCT01516541 | —Not reported |
| ApoB, % change | —Not posted · NCT01516541 | —Not reported |
| Lp(a), % change | —Not posted · NCT01516541 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT01516541 | —Not reported |
LDL-C, % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Non-HDL-C, % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
ApoB, % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Lp(a), % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
3-point MACE (% with event)
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dalcetrapib: 3 of 4 rows · Obicetrapib/ezetimibe (Evlarco): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dalcetrapib |
|---|---|
| Dropout rate | 2.1%a NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results17.2% NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2 10.8%900mg NCT00697203 · Phase 2 · registry result, not featured evidence 8.8%600mg NCT00697203 · Phase 2 · registry result, not featured evidence 11.8%300mg NCT00697203 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results— NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2 —900mg NCT00697203 · Phase 2 · registry result, not featured evidence —600mg NCT00697203 · Phase 2 · registry result, not featured evidence —300mg NCT00697203 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.9%a NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results31.3% NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2 4.1%900mg NCT00697203 · Phase 2 · registry result, not featured evidence 2.9%600mg NCT00697203 · Phase 2 · registry result, not featured evidence 2.6%300mg NCT00697203 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a chest pain 10.1% (placebo 7.8%) diarrhea 8.6% (placebo 5.8%) hypertension 8% (placebo 4.1%) NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dalcetrapib
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalcetrapib's landscape · Obicetrapib/ezetimibe (Evlarco)'s landscape